Sweden · Delayed Price · Currency is SEK Xbrane Biopharma AB Statistics
Total Valuation
STO:XBRANE has a market cap or net worth of SEK 209.14 million. The enterprise value is 223.36 million.
| Market Cap | 209.14M |
| Enterprise Value | 223.36M |
Important Dates
The last earnings date was Friday, July 17, 2026.
| Earnings Date | Jul 17, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
STO:XBRANE has 20.61 million shares outstanding. The number of shares has decreased by -97.34% in one year.
| Current Share Class | 20.61M |
| Shares Outstanding | 20.61M |
| Shares Change (YoY) | -97.34% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 16.69% |
| Owned by Institutions (%) | 5.30% |
| Float | 15.03M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.51 |
| PB Ratio | 0.39 |
| P/TBV Ratio | 0.39 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 2.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.19, with a Debt / Equity ratio of 0.12.
| Current Ratio | 3.19 |
| Quick Ratio | 0.71 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.49 |
| Interest Coverage | -24.95 |
Financial Efficiency
Return on equity (ROE) is -16.02% and return on invested capital (ROIC) is -10.62%.
| Return on Equity (ROE) | -16.02% |
| Return on Assets (ROA) | -5.83% |
| Return on Invested Capital (ROIC) | -10.62% |
| Return on Capital Employed (ROCE) | -11.77% |
| Weighted Average Cost of Capital (WACC) | 7.59% |
| Revenue Per Employee | 2.87M |
| Profits Per Employee | -2.59M |
| Employee Count | 29 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 0.37 |
Taxes
In the past 12 months, STO:XBRANE has paid 96,000 in taxes.
| Income Tax | 96,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -71.84% in the last 52 weeks. The beta is 0.85, so STO:XBRANE's price volatility has been lower than the market average.
| Beta (5Y) | 0.85 |
| 52-Week Price Change | -71.84% |
| 50-Day Moving Average | 10.65 |
| 200-Day Moving Average | 11.06 |
| Relative Strength Index (RSI) | 44.35 |
| Average Volume (20 Days) | 19,052 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, STO:XBRANE had revenue of SEK 83.30 million and -75.00 million in losses. Loss per share was -3.95.
| Revenue | 83.30M |
| Gross Profit | 11.61M |
| Operating Income | -58.07M |
| Pretax Income | -73.91M |
| Net Income | -75.00M |
| EBITDA | -63.76M |
| EBIT | -63.76M |
| Loss Per Share | -3.95 |
Balance Sheet
The company has 49.50 million in cash and 63.71 million in debt, with a net cash position of -14.22 million or -0.69 per share.
| Cash & Cash Equivalents | 49.50M |
| Total Debt | 63.71M |
| Net Cash | -14.22M |
| Net Cash Per Share | -0.69 |
| Equity (Book Value) | 538.85M |
| Book Value Per Share | 26.15 |
| Working Capital | 220.98M |
Cash Flow
In the last 12 months, operating cash flow was -130.32 million and capital expenditures -108,000, giving a free cash flow of -130.42 million.
| Operating Cash Flow | -130.32M |
| Capital Expenditures | -108,000 |
| Depreciation & Amortization | -3.27M |
| Net Borrowing | 37.36M |
| Free Cash Flow | -130.42M |
| FCF Per Share | -6.33 |
Margins
Gross margin is 13.94%, with operating and profit margins of -69.71% and -90.04%.
| Gross Margin | 13.94% |
| Operating Margin | -69.71% |
| Pretax Margin | -88.73% |
| Profit Margin | -90.04% |
| EBITDA Margin | -76.55% |
| EBIT Margin | -76.55% |
| FCF Margin | n/a |
Dividends & Yields
STO:XBRANE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 97.34% |
| Shareholder Yield | 97.34% |
| Earnings Yield | -35.86% |
| FCF Yield | -62.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 17, 2025. It was a reverse split with a ratio of 0.008.
| Last Split Date | Oct 17, 2025 |
| Split Type | Reverse |
| Split Ratio | 0.008 |
Scores
STO:XBRANE has an Altman Z-Score of 0.13 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 0.13 |
| Piotroski F-Score | 1 |